Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, May 16, 2023
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
[ Tue, May 16th 2023
] - WOPRAI
Mon, May 15, 2023
[ Mon, May 15th 2023
] - WOPRAI
Evan David Seigerman Maintained (CADL) at Buy with Decreased Target to $3 on, May 15th, 2023
Evan David Seigerman of BMO Capital, Maintained "Candel Therapeutics, Inc." (CADL) at Buy with Decreased Target from $9 to $3 on, May 15th, 2023.
Evan has made no other calls on CADL in the last 4 months.
There is 1 other peer that has a rating on CADL. Out of the 1 peers that are also analyzing CADL, 0 agree with Evan's Rating of Hold.
This is the rating of the analyst that currently disagrees with Evan
- Judah Frommer of "Credit Suisse" Maintained at Buy with Decreased Target to $7 on, Friday, March 31st, 2023
